Role of endorectal MR imaging and MR spectroscopic imaging in defining treatable intraprostatic tumor foci in prostate cancer: Quantitative analysis of imaging contour compared to whole-mount histopathology

Mekhail Anwar, Antonio C. Westphalen, Adam J. Jung, Susan M. Noworolski, Jeffry P. Simko, John Kurhanewicz, Mack Roach, Peter R. Carroll, Fergus Coakley

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Purpose To investigate the role of endorectal MR imaging and MR spectroscopic imaging in defining the contour of treatable intraprostatic tumor foci in prostate cancer, since targeted therapy requires accurate target volume definition. Materials and methods We retrospectively identified 20 patients with prostate cancer who underwent endorectal MR imaging and MR spectroscopic imaging prior to radical prostatectomy and subsequent creation of detailed histopathological tumor maps from whole-mount step sections. Two experienced radiologists independently reviewed all MR images and electronically contoured all suspected treatable (≥0.5 cm3) tumor foci. Deformable co-registration in MATLAB was used to calculate the margin of error between imaging and histopathological contours at both capsular and non-capsular surfaces and the treatment margin required to ensure at least 95% tumor coverage. Results Histopathology showed 17 treatable tumor foci in 16 patients, of which 8 were correctly identified by both readers and an additional 2 were correctly identified by reader 2. For all correctly identified lesions, both readers accurately identified that tumor contacted the prostatic capsule, with no error in contour identification. On the non-capsular border, the median distance between the imaging and histopathological contour was 1.4 mm (range, 0-12). Expanding the contour by 5 mm at the non-capsular margin included 95% of tumor volume not initially covered within the MR contour. Conclusions Endorectal MR imaging and MR spectroscopic imaging can be used to accurately contour treatable intraprostatic tumor foci; adequate tumor coverage is achieved by expanding the treatment contour at the non-capsular margin by 5 mm.

Original languageEnglish (US)
Pages (from-to)303-308
Number of pages6
JournalRadiotherapy and Oncology
Volume110
Issue number2
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Prostatic Neoplasms
Neoplasms
Prostatectomy
Tumor Burden
Capsules
Therapeutics

Keywords

  • Dominant intraprostatic lesion
  • Dose escalation
  • Focal therapy
  • MRI
  • MRSI
  • Prostate cancer

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Hematology
  • Medicine(all)

Cite this

Role of endorectal MR imaging and MR spectroscopic imaging in defining treatable intraprostatic tumor foci in prostate cancer : Quantitative analysis of imaging contour compared to whole-mount histopathology. / Anwar, Mekhail; Westphalen, Antonio C.; Jung, Adam J.; Noworolski, Susan M.; Simko, Jeffry P.; Kurhanewicz, John; Roach, Mack; Carroll, Peter R.; Coakley, Fergus.

In: Radiotherapy and Oncology, Vol. 110, No. 2, 2014, p. 303-308.

Research output: Contribution to journalArticle

Anwar, Mekhail ; Westphalen, Antonio C. ; Jung, Adam J. ; Noworolski, Susan M. ; Simko, Jeffry P. ; Kurhanewicz, John ; Roach, Mack ; Carroll, Peter R. ; Coakley, Fergus. / Role of endorectal MR imaging and MR spectroscopic imaging in defining treatable intraprostatic tumor foci in prostate cancer : Quantitative analysis of imaging contour compared to whole-mount histopathology. In: Radiotherapy and Oncology. 2014 ; Vol. 110, No. 2. pp. 303-308.
@article{16c634deceaa4ed1bad439e63efa1b4e,
title = "Role of endorectal MR imaging and MR spectroscopic imaging in defining treatable intraprostatic tumor foci in prostate cancer: Quantitative analysis of imaging contour compared to whole-mount histopathology",
abstract = "Purpose To investigate the role of endorectal MR imaging and MR spectroscopic imaging in defining the contour of treatable intraprostatic tumor foci in prostate cancer, since targeted therapy requires accurate target volume definition. Materials and methods We retrospectively identified 20 patients with prostate cancer who underwent endorectal MR imaging and MR spectroscopic imaging prior to radical prostatectomy and subsequent creation of detailed histopathological tumor maps from whole-mount step sections. Two experienced radiologists independently reviewed all MR images and electronically contoured all suspected treatable (≥0.5 cm3) tumor foci. Deformable co-registration in MATLAB was used to calculate the margin of error between imaging and histopathological contours at both capsular and non-capsular surfaces and the treatment margin required to ensure at least 95{\%} tumor coverage. Results Histopathology showed 17 treatable tumor foci in 16 patients, of which 8 were correctly identified by both readers and an additional 2 were correctly identified by reader 2. For all correctly identified lesions, both readers accurately identified that tumor contacted the prostatic capsule, with no error in contour identification. On the non-capsular border, the median distance between the imaging and histopathological contour was 1.4 mm (range, 0-12). Expanding the contour by 5 mm at the non-capsular margin included 95{\%} of tumor volume not initially covered within the MR contour. Conclusions Endorectal MR imaging and MR spectroscopic imaging can be used to accurately contour treatable intraprostatic tumor foci; adequate tumor coverage is achieved by expanding the treatment contour at the non-capsular margin by 5 mm.",
keywords = "Dominant intraprostatic lesion, Dose escalation, Focal therapy, MRI, MRSI, Prostate cancer",
author = "Mekhail Anwar and Westphalen, {Antonio C.} and Jung, {Adam J.} and Noworolski, {Susan M.} and Simko, {Jeffry P.} and John Kurhanewicz and Mack Roach and Carroll, {Peter R.} and Fergus Coakley",
year = "2014",
doi = "10.1016/j.radonc.2013.12.003",
language = "English (US)",
volume = "110",
pages = "303--308",
journal = "Radiotherapy and Oncology",
issn = "0167-8140",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Role of endorectal MR imaging and MR spectroscopic imaging in defining treatable intraprostatic tumor foci in prostate cancer

T2 - Quantitative analysis of imaging contour compared to whole-mount histopathology

AU - Anwar, Mekhail

AU - Westphalen, Antonio C.

AU - Jung, Adam J.

AU - Noworolski, Susan M.

AU - Simko, Jeffry P.

AU - Kurhanewicz, John

AU - Roach, Mack

AU - Carroll, Peter R.

AU - Coakley, Fergus

PY - 2014

Y1 - 2014

N2 - Purpose To investigate the role of endorectal MR imaging and MR spectroscopic imaging in defining the contour of treatable intraprostatic tumor foci in prostate cancer, since targeted therapy requires accurate target volume definition. Materials and methods We retrospectively identified 20 patients with prostate cancer who underwent endorectal MR imaging and MR spectroscopic imaging prior to radical prostatectomy and subsequent creation of detailed histopathological tumor maps from whole-mount step sections. Two experienced radiologists independently reviewed all MR images and electronically contoured all suspected treatable (≥0.5 cm3) tumor foci. Deformable co-registration in MATLAB was used to calculate the margin of error between imaging and histopathological contours at both capsular and non-capsular surfaces and the treatment margin required to ensure at least 95% tumor coverage. Results Histopathology showed 17 treatable tumor foci in 16 patients, of which 8 were correctly identified by both readers and an additional 2 were correctly identified by reader 2. For all correctly identified lesions, both readers accurately identified that tumor contacted the prostatic capsule, with no error in contour identification. On the non-capsular border, the median distance between the imaging and histopathological contour was 1.4 mm (range, 0-12). Expanding the contour by 5 mm at the non-capsular margin included 95% of tumor volume not initially covered within the MR contour. Conclusions Endorectal MR imaging and MR spectroscopic imaging can be used to accurately contour treatable intraprostatic tumor foci; adequate tumor coverage is achieved by expanding the treatment contour at the non-capsular margin by 5 mm.

AB - Purpose To investigate the role of endorectal MR imaging and MR spectroscopic imaging in defining the contour of treatable intraprostatic tumor foci in prostate cancer, since targeted therapy requires accurate target volume definition. Materials and methods We retrospectively identified 20 patients with prostate cancer who underwent endorectal MR imaging and MR spectroscopic imaging prior to radical prostatectomy and subsequent creation of detailed histopathological tumor maps from whole-mount step sections. Two experienced radiologists independently reviewed all MR images and electronically contoured all suspected treatable (≥0.5 cm3) tumor foci. Deformable co-registration in MATLAB was used to calculate the margin of error between imaging and histopathological contours at both capsular and non-capsular surfaces and the treatment margin required to ensure at least 95% tumor coverage. Results Histopathology showed 17 treatable tumor foci in 16 patients, of which 8 were correctly identified by both readers and an additional 2 were correctly identified by reader 2. For all correctly identified lesions, both readers accurately identified that tumor contacted the prostatic capsule, with no error in contour identification. On the non-capsular border, the median distance between the imaging and histopathological contour was 1.4 mm (range, 0-12). Expanding the contour by 5 mm at the non-capsular margin included 95% of tumor volume not initially covered within the MR contour. Conclusions Endorectal MR imaging and MR spectroscopic imaging can be used to accurately contour treatable intraprostatic tumor foci; adequate tumor coverage is achieved by expanding the treatment contour at the non-capsular margin by 5 mm.

KW - Dominant intraprostatic lesion

KW - Dose escalation

KW - Focal therapy

KW - MRI

KW - MRSI

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=84896399626&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896399626&partnerID=8YFLogxK

U2 - 10.1016/j.radonc.2013.12.003

DO - 10.1016/j.radonc.2013.12.003

M3 - Article

C2 - 24444524

AN - SCOPUS:84896399626

VL - 110

SP - 303

EP - 308

JO - Radiotherapy and Oncology

JF - Radiotherapy and Oncology

SN - 0167-8140

IS - 2

ER -